Non-Hodgkin Lymphoma

Interim data on Onco TCS evaluated

Published in Cancer Weekly, December 10th, 2002

Inex Pharmaceuticals Corporation (INEX; IEX) announced that an abstract on the company's lead product, Onco TCS, was accepted for presentation at the American Society of Hematology (ASH) annual meeting.

The abstract was accepted on the first 66 evaluable patients that have completed treatment in a phase II clinical trial evaluating Onco TCS as a first-line treatment for aggressive non-Hodgkin lymphoma (NHL). All 66 patients responded to therapy for an overall response rate of 100%. Of the 66 patients, 65 (98%) completely responded to therapy and had all of their tumors eliminated and one patient (2%) partially responded to therapy and had their tumor volume decreased...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry